Effects of GLP-1RA on Kidney Outcomes in CKD Studies The FLOW-CKD trial examined the benefits of semaglutide compared to a placebo in patients with diabetes and CKD, specifically focusing on long-term kidney outcomes (Table 2)
One study indicated that compared to the traditional standard diet, a low-fat diet with increased whole grains, vegetables, and fruits could significantly improve the OS of breast cancer patients
Without getting too deep into the science, glucagon-like peptide-1, or GLP-1, is a hormone produced in the gut when food enters the stomach
Put them together and, in theory, you get both delivery and signal at the same moment
Through these effects, HTY has also been described as an anti-inflammatory compound that can reduce the production of pro-inflammatory mediators, thereby supporting cardiovascular protection in experimental studies [72, 73]
These assessments can identify any emerging concerns before they become problematic